Steven Cohen’s Jazz Pharmaceuticals JAZZ Stock Holding History

Steven Cohen’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$193K	Sell	800 -500	-38%	-$110K	﹤0.01%	3554
2026 Q1	$246K	Buy	+1,300	New	+$227K	﹤0.01%	3445
2024 Q2	–	Sell	-6,000	Closed	-$723K	–	2146
2024 Q1	$723K	Buy	6,000 +2,000	+50%	+$245K	﹤0.01%	1545
2023 Q4	$492K	Buy	+4,000	New	+$499K	﹤0.01%	1581

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Steven Cohen's JAZZ Position: Q2 2026 in Review

Steven Cohen sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 358,634 shares — an estimated $78.6M sold.

Steven Cohen first reported a position in JAZZ in Q3 2015 and held it in 29 quarters. The position peaked at $123M in Q4 2021. 640 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Steven Cohen reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 358,634 Jazz Pharmaceuticals shares in Q2 2026, an estimated $78.6M.
Steven Cohen first reported a position in Jazz Pharmaceuticals in Q3 2015 and held it in 29 quarters.
Steven Cohen's Jazz Pharmaceuticals position peaked at $123M in Q4 2021.
640 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.